heart iconheart icon
Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Dec 5, 2001
NEW ORLEANS, Nov. 14 -- Cordis Cardiology reported today U.S. market introduction of its new Bx VELOCITY(TM) Coronary Stent with Hepacoat(TM) -- the first drug-coated stent utilizing a proprietary heparin coating to receive regulatory approval in the U.S. and Europe. Cordis Cardiology is a unit of Cordis Corporation, a Johnson & Johnson company. ...
Dec 5, 2001
ANAHEIM, Calif., Nov. 13-- Pilot clinical results to be presented today at annual scientific sessions of the American Heart Association show the potential for Cordis Corporation's CYPHER(TM) Sirolimus-eluting Stent to markedly reduce in-stent restenosis in patients with coronary artery disease. Funded by a grant from Cordis, the ISR (In-Sten...
Nov 21, 2001
Johnson & Johnson to Participate in The Second Annual Merrill Lynch Med Tech Fundamentals Conference NEW BRUNSWICK, N.J., Nov 21, 2001 -- Johnson & Johnson will participate in The Second Annual Merrill Lynch Med Tech Fundamentals Conference at the Metropolitan Club in New York on Wednesday, November 28, 2001. There will be panel presentatio...
Nov 21, 2001
NEW BRUNSWICK, N.J., Nov 21, 2001 -- Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly based manufacturer of health care products, today announced the completion of its previously announced acquisition of Inverness Medical Technology, excluding certain businesses. The transaction was completed today after Inverness sharehold...
Nov 19, 2001
NEW BRUNSWICK, N.J., Nov. 16-- Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly based manufacturer of health care products, announced today that its proposed acquisition of Inverness' diabetes care products business and the split-off of Inverness' women's health, nutritional supplements and clinical diagnostics businesses a...
Nov 5, 2001
NEW YORK STOCK EXCHANGE--Ringing the opening bell at the NYSE to celebrate the 12th anniversary of Johnson & Johnson-Merck Consumer Pharmaceuticals Co. and the launch of new Pepcid® Complete, the first and only fast and long-lasting heartburn remedy, will be Peter K. Miller, President of Johnson & Johnson-Merck Consu...
Oct 25, 2001
NEW BRUNSWICK, N.J., Oct. 25 -- Johnson & Johnson (NYSE: JNJ) today announced the signing of an agreement to buy the 40 percent equity stake in its Japanese pharmaceutical joint venture, Janssen-Kyowa Co., Ltd., held by its Japanese partner, Kyowa Hakko Kogyo Co., Ltd. The terms of the agreement were not disclosed. Johnson & Johnson has owned ...
Oct 24, 2001
NEW BRUNSWICK, N.J., Oct 24, 2001 that it is seeking FDA permission to add anthrax as an approved indication for its broad-spectrum anti-infective, LEVAQUIN. The company said it is prepared to make available up to 100 million tablets free of charge to the Federal government for use as it determines appropriate, assuming FDA approval. The comp...
Oct 22, 2001
NEW BRUNSWICK, N.J. and WALTHAM, Mass., Oct 22, 2001 -- Johnson & Johnson (NYSE: JNJ), the world's most comprehensive and broadly based manufacturer of health care products, and Inverness Medical Technology (Amex: IMA), a developer of innovative products focused primarily on the self-management of diabetes, today announced that the Securities and E...
Oct 16, 2001
NEW BRUNSWICK, N.J., Oct. 16 -- Johnson & Johnson today announced sales of $8.2 billion and net earnings of $1.5 billion for the third quarter of 2001, increases of 10.8% and 15.6%, respectively, over third quarter 2000 results. Diluted earnings per share for the third quarter were $.49, up 14.0% from the same period in 2000. Excluding the impact o...
Oct 9, 2001
NEW BRUNSWICK, N.J., Oct 9, 2001 -- Johnson & Johnson will release third-quarter earnings and host a conference call for financial analysts at 8:30 a.m. on Tuesday, October 16, 2001. Robert J. Darretta, Vice President, Finance, Chief Financial Officer and member of the Executive Committee, and Helen E. Short, Vice President, Investor Relations, wi...
Sep 24, 2001
NEW BRUNSWICK, N.J., Sep 24, 2001 -- Johnson & Johnson will host a webcast presentation to analysts on its Cordis business unit on September 27, 2001 from 4:00 - 5:30 p.m. (E.D.S.T.). There will be formal presentations by Company Group Chairman Robert W. Croce and senior members of Cordis management. A question and answer session will follow the p...
Sep 21, 2001
NEW BRUNSWICK, N.J., Sep 21, 2001 -- Johnson & Johnson will participate in the Bear Stearns 2001 Health Care "Virtual" Conference on Wednesday, September 26, 2001 at 3:00 p.m. (E.D.S.T.). There will be a formal presentation on Johnson & Johnson by William C. Weldon, Vice Chairman, Board of Directors and Christine Poon, Worldwide Chairman, Pharmace...
Sep 17, 2001
RARITAN, N.J., Sept. 17 -- The R. W. Johnson Pharmaceutical Research Institute (RWJPRI), a subsidiary of Johnson & Johnson (NYSE: JNJ), has completed evaluation of the results of three pivotal clinical trials conducted with topiramate in patients with diabetic neuropathy. In each trial, topiramate failed to demonstrate a statistically significant d...
Sep 17, 2001
NEW BRUNSWICK, N.J., Sep 17, 2001 -- The following is a summary of aid and contributions provided by Johnson & Johnson to support disaster relief efforts in New York City: Johnson & Johnson has pledged a package of $10 million in financial and product aid to help meet the needs of those affected by last week's terrorist attacks on America....
= add release to Briefcase